Optimised crystallisation, purity, and yield
Integrated molecular, process, impurity, and analytical insight
Molecular and bulk property understanding for formulation
Aligned with regulatory expectations for characterisation and impurity data
Optimise physical form for clinical success
Salt form, polymorphism, and morphology directly impact solubility, stability, and bioavailability which are key drivers of clinical performance and regulatory success. We deliver phase-appropriate screening and optimisation to ensure your API is ready for formulation and scale-up.
Key capabilities
Our capabilities support every stage of development – from early pre-formulation to commercialisation and lifecycle management. These include:
- Solid-state characterisation
- Polymorph and salt screening
- Co-crystal and crystallisation development
- Impurity control strategies
- Solubility and stability studies
- Pre-formulation support
Advanced analytical techniques
Using carefully designed experimental strategies, we generate highly predictive datasets that inform both upstream process development and downstream formulation.
- X-Ray Powder Diffraction (XRPD)
- Differential Scanning Calorimetry (DSC)
- Thermogravimetric Analysis (TGA)
- Solid-State NMR spectroscopy
- Dynamic Vapour Sorption (DVS)
- FTIR spectroscopy
- Optical microscopy
Arcinova: Your partner in solid-state science
Optimise performance through smart salt selection
Reduce risk with comprehensive polymorph screening
Integrate solid-state with process development
Accelerate candidate progression with pre-formulation insight
Solid-State Characterisation
Strengthen your formulation with smart salt selection
Salt form screening can improve bioavailability and unlock better physical and chemical properties for your drug substance. That’s why early evaluation is critical – not only to optimise product performance, but to support IP protection and long-term lifecycle management. We perform comprehensive salt screening to identify the most suitable form based on pKa, lipophilicity, intended dosage form, and known molecular interactions to move your programme forward confidently.
End-to-end development support
Our integrated teams bring together process chemistry, solid-state science, analytical development, formulation expertise, and GMP manufacturing to streamline development and accelerate time to clinic. By combining solid-form screening and selection with development and manufacturing activities, we identify the optimal solid form ahead of manufacture, reducing handoffs, enabling faster decision-making, and supporting efficient progression to IND/IMPD and beyond.
Bring your candidate to clinic faster with pre-formulation screening support
Our experienced material scientists support early pre-formulation screening to identify the most suitable form of your drug substance – with the right physicochemical properties to progress into preclinical and early clinical development. Our integrated approach streamlines decision-making, supports better candidate selection, and lays the foundation for a successful drug product.
Accelerate API isolation and purification through integrated solid-state support
Our end-to-end drug substance development capabilities bring together process research, analytical science, solid-state expertise and GMP manufacture Our solid-state team works hand-in-hand with Process Research & Development to rapidly determine salt forms and map polymorphic landscapes to integrate crystallisation development with process optimisation – ensuring the selected form enhances yield, solubility, stability and chemical purity.
